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Abstract: Multidrug resistance (MDR) to anticancer drugs is a serious health problem that in many
cases leads to cancer treatment failure. The ATP binding cassette (ABC) transporter P-glycoprotein
(P-gp), which leads to premature efflux of drugs from cancer cells, is often responsible for MDR. On the
other hand, a strategy to search for modulators from natural products to overcome MDR had been in
place during the last decades. However, Nature limits the amount of some natural products, which has
led to the development of synthetic strategies to increase their availability. This review summarizes
the research findings on marine natural products and derivatives, mainly alkaloids, polyoxygenated
sterols, polyketides, terpenoids, diketopiperazines, and peptides, with P-gp inhibitory activity
highlighting the established structure-activity relationships. The synthetic pathways for the total
synthesis of the most promising members and analogs are also presented. It is expected that the
data gathered during the last decades concerning their synthesis and MDR-inhibiting activities will
help medicinal chemists develop potential drug candidates using marine natural products as models
which can deliver new ABC transporter inhibitor scaffolds.
Keywords: ABC transporters; P-glycoprotein modulators; marine natural products; multidrug
resistance (MDR); synthesis; structure activity relationship (SAR)
1. Introduction
It is well known that cancer figures among the leading causes of morbidity and mortality [1].
Despite many advances in therapy, diagnosis, and prevention, cancer remains a deadly disease.
Although the general term cancer covers many different diseases, most disseminated cancers share a
common feature of not responding to available chemotherapies. The remorseless onset to resistance to
a wide variety of structurally and mechanistically unrelated anticancer drugs, known as multidrug
resistance (MDR), is the major obstacle for a successful human cancer therapy [2]. This eventually
leads to cancer relapse and death. Some cancers such as gastrointestinal and renal cancers are largely
unresponsive to chemotherapy, i.e., they have a high degree of intrinsic MDR, whereas leukemias,
lymphomas, ovarian, and breast cancers often respond to initial treatment, but then acquire MDR
during the course of the disease [3]. MDR to anticancer drugs is therefore a serious health problem
that dramatically affects the efficacy of cancer treatments [4]. MDR is a phenomenon by which
cancer cells develop broad resistance to a wide variety of structurally and functionally unrelated
compounds which may arise from several mechanisms [5,6] including: (i) decreased cellular drug
uptake; (ii) activation of detoxifying enzymes; (iii) alterations in the molecular targets of the drugs;
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(iv) defective apoptotic pathways; and (v) increased drug efflux [6–9]. One of the most prominent
mechanisms of MDR to cytotoxic drugs is usually associated with the overexpression of ATP-binding
cassette (ABC)-transporter proteins in the tumor cells. Due to the increased efflux out of cells, these
pumps can lead to a reduced cellular accumulation of anticancer drugs. These proteins mediate MDR
not only in drug entry, but also in drug sequestration by lysosomes, phase III metabolism, mechanisms
activated after nuclear entry, apoptosis, microenvironment, and signal transduction pathways that
lead to the overexpression of genes that codify these ABC transporters [10]. Such proteins belong to a
large family of 49 genes, classified in seven subfamilies (A–G), with several transporters involved in
MDR [11]. These include P-glycoprotein (P-gp or ABCB1), multidrug resistance associated proteins
1-6 (MRP1-6 or ABCC1-6), and breast cancer resistance protein (BCRP or ABCG2) [12]. P-gp is the best
characterized efflux pump mediating MDR due to its broadest substrate specificity and widest tissue
and organ distribution. This 170 kDa glycoprotein acts as a drug efflux pump for a wide variety of
anticancer agents such as anthracyclines and epidodophyllotoxins, thus limiting their bioavailability
and activity. P-gp is encoded by the human MDR-1 gene, which is located at chromosome 7. It contains
1280 amino acids, arranged in two halves, each encompassing a transmembrane domain (TMD) which
spans the membrane and an intracellular nucleotide-binding domain (NBD) [13,14].
Several studies have already correlated P-gp expression with resistance to chemotherapeutic
drugs, particularly in leukemia cells [15]. Furthermore, down-regulation of P-gp expression was
shown to sensitize several tumor-resistant cell lines to chemotherapeutic drugs. Indeed, the use of
antisense or rybozyme targeting MDR-1 gene has led to the sensitization of acute myeloid leukemia
(AML), ovarian, colon, and breast cancer cells to doxorubicin as well as to increase the sensitivity of
chronic and AML cells to daunorubicin [16,17].
It was found that P-gp could be expressed in Chinese hamster ovary cells, selected for colchicine
resistance, almost 40 years ago, and since then there has been an ongoing effort to develop therapies
that could either block or inactivate this transporter to increase the concentration of anticancer drugs
within cells [18]. First generation of P-gp inhibitors referred to drugs already in clinical use or under
investigation for therapeutic ability e.g., verapamil, quinidine, and cyclosporine A [19]. However, most
of the first generation P-gp inhibitors were found to lack selectivity for P-gp and being substrates for
other transporters and enzyme systems; this promiscuity resulted in unpredictable pharmacokinetic
interactions in the presence of anticancer drugs [20]. Moreover, low affinity for P-gp, associated
with the original therapeutic activity, required the use of high doses which resulted in unacceptable
toxicity [6,21]. Second generation of P-gp inhibitors were developed, based on the selective optimization
of side activity (SOSA) approach, to increase the potency and reduce toxicity, many of which were
single enantiomers of the first generation drugs. An example of these is dexverapamil which is
an R-enantiomer of verapamil. Interestingly, many of the second generation P-gp inhibitors such as
valspodar (PSC-833), elacridar (GF 120918), and biricodar, also entered clinical trials [6]. Although some
of the second generation inhibitors showed better pharmacological profiles in clinical trials, they still
had limited use as P-gp modulators since most of them were found to be substrates of cytochrome
P450 3A, thus interfering with the metabolism and excretion of co-administered chemotherapeutic
agents [22]. The third generation of P-gp inhibitors, which exhibited P-gp inhibitory activity at
nanomolar concentrations, were developed to overcome the referred problems through quantitative
structure-activity relationships (QSAR) studies and combinatorial chemistry approaches [23]. Since the
third generation of inhibitors that entered clinical trials did not interfere with cytochrome P450
3A4, they did not reveal any interference with pharmacokinetics of anticancer drugs [24]. One of
the most popular third generation P-gp inhibitors is tariquidar, however, its phase III studies on
non-small cell lung cancer patients were terminated due to its high toxicity [25]. The same unwanted
results were observed with other third generation inhibitors like zosuquidar, elacridar, laniquidar, and
ontogeny [20,26]. Although phase I and II trials were performed with some third generation P-gp
inhibitors, an emerging consensus, in 2010, was that P-gp should be taken off the list of druggable
targets due to the failure of zosuquidar to show clinical benefits in phase III clinical trials [27]. Until now,
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the existing P-gp inhibitors have demonstrated limited clinical success due to their limitations in
potency and specificity and also to their interactions with anticancer drugs. Moreover, QSAR and
docking studies also could not produce promising hits or leads for safe and effective compounds.
As there is a permanent need to identify and validate new antitumor agents, with novel mechanisms
of action, more efficient P-gp inhibitors are needed.
Recently, there has been a proposal of a new generation of ABC inhibitors which focuses on
natural products and natural product mimics [28–30], peptidomimetics [31], surfactants and lipids [32],
and dual ligands [20]. While the traditional sources of terrestrial plants and microbes will undoubtedly
continue to yield valuable new bioactive agents, it is even more important to explore all available
pools of molecular diversity. This strategy to seek out new ecosystems for bioprospecting brings with
it the opportunity to discover unprecedented molecular structures, with bioactivities unencumbered
by known (and evolving) mechanisms of drug resistance [33]. Marine natural products are one of
the most interesting targets for global drug discovery since they not only possess structural and
chemical uniqueness but also represent novel scaffolds for drug development [34]. Marine natural
products have also been studied and tested alongside with synthetic compounds as ABC transporter
inhibitors [29,35–38]. The development of anticancer drugs from marine compounds is one of the
most promising approaches in drug discovery with therapeutic agents in clinical practice, such as the
anticancer trabectedin [37]. Recently, marine natural products and their analogs with antitumor activity
have been developed, and many of them have shown also ability for ABC modulation. Thus, marine
natural products are revealing an interesting potential in this field not only for the possibility of being
used in combination with other anticancer drugs but also as dual inhibitors of tumor cell growth and
P-gp. Thus, they could be of value in the rational design of analogs with high potential and reduced
pharmacokinetic interactions.
There are already several reviews which highlighted the importance of marine natural products in
cancer and, in particular, as P-gp modulators [29,35,39–43]. However, this review aims to describe not
only the effects of the most valuable scaffolds from marine natural products and analogs in overcoming
MDR but also their synthetic pathways. These data along with structure-activity relationship
herein described could serve to guide medicinal chemists in pursuing innovative inhibitors of ABC
transporters using marine natural products as models.
2. Marine Natural Products and Derivatives as Inhibitors of ABC Transporters
2.1. Terpenoids
2.1.1. Sipholane Triterpenoids and Derivatives
The sipholane triterpenes are compounds that contain a perhydrobenzoxepin (rings A and B)
and a [5,3,0] bicyclodecane ring systems (rings C and D) linked together by an ethylene group
(Figure 1). This class of triterpenes consists of sipholenol A (1), sipholenone E (2), sipholenol L (3), and
siphonellinol D (4), isolated from the Red Sea sponge Callyspongia siphonella [44,45], and semisynthetic
derivatives of sipholenol A such as sipholenol A-4-O-acetate (5), sipholenol A-4-O-isonicotinate
(6) [39], sipholenol A-4-O-3’,4’-dichlorobenzoate (7) [46], sipholenol A 4-O-4’-chlorobenzoate (8), and
19,20-anhydrosipholenol A 4-O-4’-chlorobenzoate (9) [47] that were synthesized using a ligand-based
design approach. Natural and semisynthetic siphonane triterpenoids were shown to reverse MDR
activities (1–6), and display antimigratory and antiproliferative activities in breast cancer cell lines
(7–9). Sipholenol A (1) was shown to be potent in reversing MDR KB-C2 [48] and KB-V1 tumor
cells with overexpressed P-gp, in a concentration-dependent manner. Compound 1 also inhibited
P-gp-mediated drug efflux and did not alter the expression of P-gp after treatment in KB-C2 and
KB-V1 cells. This compound stimulated the activity of ATPase, and also inhibited the photo-labeling
transporter with [125I]-iodoarylazidoprazosin [44]. From SAR studies (Figure 1), it was demonstrated
that substitution of the methyl group on C-15 by carbonyl or alcohol reduced the MDR-inhibitory
activity, while changing from a hydroxyl to a ketone function at C-4 also reduced the activity [48].
Molecules 2016, 21, 892 4 of 51
Compounds 2, 3, and 4 also enhanced the cytotoxicity of several P-gp substrates including colchicine,
vinblastine, and paclitaxel, and reversed the MDR-phenotype in P-gp-overexpressing MDR KB-C2
tumor cells, in a dose-dependent manner [45]. Compound 2 was reported as a better P-gp inhibitor
than 1 in KB-3-1 and KB-C2 cell lines [49], while 3 and 4 also showed a reversal of MDR in the same
tumor cells, but did not reveal the effect on cells lacking P-gp expression or expressing MRP1, MRP7,
or BCRP transporters [36,45,49].
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Figure 1. Structures of sipholane triterpenes 1–4 and their analogs 5–9. Dashed circles indicate SAR
studies performed for MDR activities.
The semisynthetic esters 5 and 6 were found to strongly reverse P-gp (ABCB1)-mediated
MDR, however they showed no effect on MRP1/ABCC1 and BCRP/ABCG2-mediated MDR.
These analogs increased the intracellular accumulation of paclitaxel through inhibition of its active
efflux, and re-sensitized cells that ha e developed drug-resistance to doxorubicin and paclitaxel.
These two compo nds stimulated more intensiv ly the ATPase activity of P-gp membranes than 2, 3,
and 4. In silico molecular d cking study, by the insp ction of e virtual binding modes of compounds
5 and 6 into human homology model of P-gp, rev aled t at both compounds wer overlapped but
with differe t molecular orientation of ester substituents. Their strong affinity and specificity to P-gp
expressing efflux protein indicated that compounds 5 and 6 may represent a potential reversal agents
for treatment of MDR cancers [39]. The synthesis of the ester analogs 8 and 9 is presented in Scheme 1,
to highlight the strategy involved (using a ligand-based design approach).
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Scheme 1. The semi-synthesis transformation of sipholenol A (1) into analogs 8 and 9. Reagents and
conditions: (1) acid anhydride, MDAP, anhydrous CH2Cl2; (2) p-toluenesulfonic acid, CHCl3; (3) acid
anhydride, MDAP, anhydrous CH2Cl2.
2.1.2. Parguerenes and Derivatives
Parguerenes I (10) and II (11) (Figure 2) are bromoditerpenes, isolated from the Australian red
alga, Laurencia filiformis [50]. Several brominated diterpenes of the parguerenes and isoparguerenes
isolated from red alga Jania rubens were reported to have antitumor, anti-helmintic, and antimicrobial
activities [51]. Parguerene derivatives with cytotoxic activity on P388 and HeLa tumor cells possessed
an acet y group at C-2 and a bromine at C-15 [52]. Compounds 10 and 11 were found to
be non-cytotoxic and ose-dependent inhibitors of P-gp mediated drug efflux of verapam l and
cyclosporine A. It was also po ted that 10 and 11 are capable of reversing P-gp mediated vinblastine,
doxorubicin, and paclitaxel in cells overexpressing both P-gp (SW620/ADV300, CEM/VLB100, and
HEK93/AB B1) and MRP1 (2008/MRP1), in a dose-depende t manne . However, their inhibitory
effect did not extend to BCRP. Compounds 10 and 11 interact wit P-gp by disturbing the extracellular
antibody binding epitope of P-gp differently from existing P-gp inhibitors [53]. Therefore, the use of
this scaffold as a model for the synthesis of new MDR reversal agents could be of value. To the best of
our knowledge, the synthesis of parguerenes has not yet been reported.
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2.2. Sterols
2.2.1. Agosterol and Derivatives
Agosterol A (12, Figure 3), a polyhydroxylated sterol acetate isolated from the marine sponge
Spongia sp. [54], was found to completely reverse MDR to colchicine in human carcinoma cells KB-C2
and to vincristine in KB-CV60 (overexpressing MRP1) [55]. Compound 12 was reported to have a dual
effect on MRP1 function by reducing MRP1-mediated [3H]-LTC4 and enhancing the accumulation
of [3H]-vincristine in KB/MRP cells to the control levels. It also enhances the ATP-dependent efflux
and reduces glutathione intracellular concentration [56]. Therefore, 12 has inhibitory effects on both
P-gp and MRP1. The effect of analogs of 12, including agosterol B, C, A4, D2, A5 and C6, on MDR in
tumor cells was also investigated. Agosterol C was found to be a proteasome inhibitor [57]. From the
SAR studies, it was possible to infer that the acetoxy groups on C-3, C-4, and C-6, and the hydroxyl
groups on C-11 and C-12 were crucial for MDR reversal activity for binding to the C-terminal of MRP1
(Figure 3) [58,59]. 4-Deacetoxyagostrol A (13) showed a similar MDR-modulating activity against KB
CV-60 cell overexpressing MRP [60].
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The first synthesis of 12 from ergosterol utilizing regioselective epoxy function cleavage and
regioselective dehydroxylation as key reactions, and affording a 3.5% yield after 23 steps, was reported
in 2001 [61]. The synthetic pathway started with the oxidative cleavage of the C-22/C-23 double bond of
ergosterol to introduce a hydroxyl group to C-22, followed by a regioselective reductive epoxy cleavage
of the 9α,11α-epoxide to form an 11α-hydroxyl group. The next step was the introduction of a C-3/C-4
double bond which, after a selective dehydroxylation, afforded 3β,4β-dihydroxyl groups. Finally, a
differential removal of the protecting group and acetylation afforded 12 (Scheme 2). Compound 13
was also synthesized from ergosterol by reductive regioselective epoxy-cleavage reaction similar to
that of 12 [60].
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Scheme 2. The synthetic pathway of agosterol A (12). Reagents and conditions: (1) MOMCl, iPr2NEt,
CH2Cl2; (2) phthalhydrazide, Pb( c) , 2Cl2, AcOH, two steps; (3) O3,CH Cl2, pyridine, then
Me2S; (4) 3-methylbutylmagnesium bromide, THF, two steps; (5) TMAD, PMe3, p-OCH3BzOH,THF;
(6) LiAlH4, THF; (7) (S)-(´)-MTPA[(R)-(+)-MTPA], EDCl. Cl, D AP, CH2Cl2; (8)TBSOTf, 2,6-lutidine,
DMF-CH2Cl2; (9) Hg(OAc), EtOH/C Cl /AcOH; (10) 4-phenyl-1,2,4-triazoline-3,5-dione, CH2Cl2;
(11) mCPBA, CHCl3; (12) LiAlH4, THF; (13) TBSOTf, 2,6-lutidine, toluene; (14) Fe(CO)3,
1-(4-methyoxyphenyl)-4-pheynyl-1-azabuta-(E,E)-1,3-diene, PhCH3; (15) MgBr2-Et2O, Me2S, CH2Cl2;
(16) TsCl, pyridine, quant.; (17) DBN, PhH, quant.; (18) OsO4, pyridine, then aq. NaHSO3; (19) TESOTf,
pyridine, quant.; (20) Me3NO, PhH; (21) BH3Me2S, THF, then H2O2, aq. NaOH; (22) TBAF, THF;
(23) Ac2O, pyridine; HF, pyridine, THF.
2. . . Polyoxygenated Steroids and Derivatives
A number of polyoxygenated steroids has been isolated from gorgonians (Isis hippuris [62] and
Leptogorgia sarmentosa [63]), soft c r ls ( arco to sp. [64] and Sinularia sp. [65]), echinoderms,
and sponges [62]. Interestingly, all the polyoxygenated steroids i sti t f r antitumor [6 ],
antibacterial [64], antifungal [64], and reversing MDR [62] activities contain the char cteristic
3β,5α,6β-hydroxyl oiety. Among th se derivative are a spiroketal hippurinstanol (14),
hippuristerone (15), which possesses a 3-keto group, and the cyclopropane-containing gorgosterols
(16–20) (Figure 4) [62,64]. Polyoxygenated steroids 14–20 also differ in the side chains. Some of them
(compounds 16–20) have been tested against KB-C2 overexpressi g P-gp cells an showed moderate
activity at the concentration of 3 µM by inhibiting the growth of this resistance cell line. Compounds 17
and 18 were the most potent against KB-C2 cells [62].
Semi-synthetic derivati es of 3,16,20-polyoxygenated cholestanes, namely (20S)-hydroxy-cholestane-
3,6-dione (21), (16S,20S)-dihydroxycholestan-3-one (22), (20S)-hydroxycholest-1-ene-3,16- dione (23),
and (20S)-hydroxycholest-4-ene-3,16-dione (24) were t sted for cytotoxicity against three tumor cell
lines, i.e., human breast adenocarcinoma (MCF7), human small-cell l ng carcinoma (NCI-H187), and
human epidermoid carci oma of cavity (KB).
Compounds 23 and 24 showed strong activity against NCI-H187, and moderate activity against
MCF-7 and KB, while compound 21 di not show any activity [63]. Although no MDR-reversal
activities wer described, these compounds provided a promising synthetic ap roach for natural
polyoxygenated steroids. The synthesis of these four analogs, 21–24, was conducted through four
reaction steps, using tigogeni as a starting material, as shown in Scheme 3.
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The synthetic pathway started with the transformation of a spiroketal functionality of tigogenin to
a keto ester using the method previously described by Micovic et al., and modified by Fushs et al. [67].
The keto ester I was then transformed to a trihydroxyl intermediate II by Grignard reagent which,
after oxidation, gave compounds 21 and 22. Dehydrogenation of 21 then afforded 23 and 24 [63].
In addition, the introduction of epoxidation and dihydroxylation in suitable positions of steroid
nucleus containing oxygenated functions was reported by using transition metal-based oxidants such
as methyltrioxorhenium-hydrogen peroxide system, ruthenium tetraoxide, osmium tetraoxide, and
potassium permanganate [68].
Molecules 2016, 21, 892 8 of 50 
 
which, after oxidation, gave compounds 21 and 22. Dehydrogenation of 21 then afforded 23 and 24 
[63]. In addition, the introduction of epoxidation an  dihydroxylation in suitable positions of steroi  
n cle s containing oxygenate  f nctions as re orte  by sing transition etal-base  oxi ants s ch 
as et yltrioxor e i - y roge  eroxi e syste , r t e i  tetraoxi e, os i  tetraoxi e, a  
otassi  er a ga ate [68]. 
 
Figure 4. The structures of polyoxygenated steroids 14–20, and SAR for polyoxygenated steroids with 
antitumor activity in overexpressing P-gp cells. 
Figure 4. The structures of polyoxygenated steroids 14–20, and SAR for polyoxygenated steroids with
antitumor activity in overexpressing P-gp cells.
Molecules 2016, 21, 892 9 of 51
Molecules 2016, 21, 892 9 of 50 
 
 
Scheme 3. The synthesis of 3,16,20-polyoxygenated steroids 21–24. Reagents and conditions: (1) I: 
NH4Cl, pyridine, AcOH; II: CrO3, AcOH, H2O, (CH2Cl2)2; (2) 4-methylpentylmagnesium bromide, 
THF; (3) PCC, NaOAc, CH2Cl2; (4) Ph2Se2, m-iodomybenzoic acid, toluene, reflux. 
2.3. Polyketides 
2.3.1. Bryostatin and Derivatives 
Bryostatins are highly oxygenated marine macrolides with a polyacetate backbone [69], and more 
than 20 analogs have been isolated from the marine bryozoans Bugula neritina and Amathia convuluta 
[70]. Most of bryostatins possess antineoplastic activity in many cancer systems like M5076 sarcoma, 
L10AB cell, and mouse lymphogenous metastatic model SCID.  
Bryostatin 1 (25, Figure 5) was reported to down-regulate MDR-1 and BCL-2, but up-regulates BAX 
(induction of apoptosis) [71,72]. Spitaler et al. reported that 25 interacted with the mutated MDR-1-V185 
and the wild-type MDR-1-G185, but reversed MDR and inhibited drug efflux only in P-gp-V185 
mutants [72]. The mechanism of regulating MDR for 25 was also reported as protein kinase C (PKC) 
independent, and it seems to interact directly with MDR-1 encoded P-gp [73]. However, in a human 
breast cancer cell line (MCF-7), 25 only decreases P-gp phosphorylation after 24 h treatment in a 
concentration of 100 nM, but did not affect P-gp function in the intracellular accumulation of [3H]-
vinblastine and rhodamine 123 [74].It was found that C-1 to C-9 segment of bryostatins is suitable for 
both synthetic and biological investigation, and this segment was prepared from an inexpensive and 
easily accessible compound 2,2-dimethyl-8-oxabicyclo[3,2,1]oct-6-en-3-one [69]. Merle 23 (26, Figure 5), 
is a synthetic analog of bryostatin and whose structure differs from that of bryostatin 1 (25) in four 
positions of the space domain fragment. Interestingly, merle 23 (26) showed phorbol ester-like behavior 
not that of bryostatin in a human prostate cancer cell line (LNCaP), and this finding provided a 
powerful tool to dissect bryostatins’ mechanisms and responses [75,76]. 
The synthesis of bryostatin analog 27 (Scheme 4a) without ring A and with simplified ring B was 
carried out by a convergent esterification-macrotransacetalization procedure to couple the recognition 
(C-17–C-27) and the spacer (C-1–C-16) domain fragments (Figure 5) [70]. The synthetic pathway 
involves an allylation of an appropriate alcohol I to give the ether intermediate II. Hydroboration of 
Scheme 3. The synthesis of 3,16,20-polyoxygenated steroids 21–24. Reagents and conditions: (1) I: NH4Cl,
pyridine, AcOH; II: CrO3, AcOH, H2O, (CH2Cl2)2; (2) 4-methylpentylmagnesium bromide, THF;
(3) PCC, NaOAc, CH2Cl2; (4) Ph2Se2, m-iodomybenzoic acid, toluene, reflux.
2.3. Polyketides
2.3.1. Bryostatin a d Der vatives
Bryostatins are highly oxygenated marine macrolides with a polyacetate backbone [69],
and more than 20 analogs have been isolated from the marine bryozoans Bugula neritina and
Amathia convulu [70]. Most of bryo tatins possess antineoplastic activity in many cancer ystems like
M5076 sarcoma, L10AB cell, and mouse lymphogenous metast tic model SCID.
Bryostatin 1 (25, Figure 5) was reported to down-regulate MDR-1 and BCL-2, but up-regulates
BAX (induction of apoptosis) [71,72]. Spitaler et al. reported that 25 interacted with the mutated
MDR-1-V185 and the wild-type MDR-1-G185, but reversed MDR and inhibited drug efflux only in
P-gp-V185 mutants [72]. The mechanism of regulating MDR for 25 was also reported as protein kinase
C (PKC) independent, and it seems to interact directly with MDR-1 encoded P-gp [73]. However, in a
human breast can er cell ine (MCF-7), 25 only decreases P-gp hosphorylation after 24 h treatment
in a concentration of 100 nM, but did not affect P-gp function in the intracellular accumulation of
[3H]-vinblastine and rhodamine 123 [74]. It was found that C-1 to C-9 segment of bryostatins is
suitable for both synthetic and biological investigation, and this segment was prepared from an
inexpensive and easily accessible compound 2,2-dimethyl-8-oxabicyclo[1–3]oct-6-en-3-one [69]. Merle
23 (26, Figure 5), is a synthetic analog of bryostatin and whose structure differs from that of bryostatin
1 (25) in four positions of the space domain f agment. Interestingly, merle 23 (26) showed phorbol
ester-like behavior ot that of bryostatin in a human prostate canc r cell line (LNCaP), and this finding
provided a powerful tool to dissect bryostatins’ mechanisms and responses [75,76].
The synthesis of bryostatin analog 27 (Scheme 4a) without ring A and with simplified ring B was
carried out by a convergent esterification-macrotransacetalization procedure to couple the recognition
(C-17–C-27) and the spacer (C-1–C-16) domain fragments (Figure 5) [70]. The synthetic pathway
involves an allylation of an appropriate alcohol I to give the ether intermediate II. Hydroboration of
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the ether intermediate II, followed by oxidation gave the appropriate aldehyde III, which was then
subjected to an oxidative cleavage reaction to furnish the spacer domain. A Yamanguchi esterification
was used to produce the next intermediate IV, after which macrotranscetalization and deblocking of
C-26 alcohol were accomplished to yield bryostatin analog 27 in 11 steps (Scheme 4a) [77].
Trost et al. reported the synthesis of the bryostatin analog 28 with cross-metathesis approach at
C-16–C-17 bond using ruthenium and palladium coupling methodologies for the synthesis of B- and
C-rings [78,79]. The synthetic pathway of the spacer domain started from (R)-pantolactone and a
protected alcohol to produce the intermediate V. The coupling of the intermediate V with an alkyne
afforded B-ring pyran. The A-ring ketal was formed by deprotection and cyclization reactions, and the
spacer domain VI was formed by deprotection, oxidation, and olefination (Scheme 4b). The C-ring
fragment was prepared from a lactonized sugar using Roy’s approach [80], and the recognized domain
VII was obtained as described in Scheme 4c. Finally, a Shiina esterification was used to join VI and
VII to give 28 with 36% yield [79].
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Et3N, DMAP, CH2Cl2, rt; (11) HF·pyridine, CH3CN, rt; (12) Amberlyst-15 resin, CH2Cl2, rt; (13) 
Pd(OH)2, H2, EtOAc, 1 atm; (b) (1) 10 mol % of [CpRu(CH3CN)3]PF6, acetone, rt; (2) NBS, DMF 
then BF3-OEt2, 1,3-propanedithiol, CH2Cl2, 0 °C then PPTS, CH3OH, CH(OCH3)3, refux; (3) TESCl, 
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NaHPO4, CH2Cl2/CH3CN/ CH3OH, 0 °C; Dess-Martin oxidation; NaBH4, CeCl3·7H2O, −30oC; Ac2O, 
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Scheme 4. Synthesis of the methyl bryostatin 1 (25) analogs 27 (a) and 28 (b,c). Reagents and conditions:
(a) (1) NaH, allybromide, THF, rt; (2) Dess-Martin periodinane, CH2Cl2, rt; (3) t-BuLi, Et2O, ´78 ˝C,
(recyclable 1:1 diastereomer mixture: Dess-Martin periodinane, CH2Cl2, rt, then NaBH4, CeCl3¨ 7H2O,
´40 ˝C; (4) t-BuOH, allyl bromide, THF, rt; (5) 9-BBN, THF, 66 ˝C, then NaOH, H2O2; (6) Dess-Martin
periodinane, CH2Cl2, rt; (7) (´)-(lpc)BOMe, allylmagnesium bromide, CH2Cl2, ´78 ˝C to rt; (8) TBSCl,
imidazole, THF, rt; (9) catalytic KMnO4, NaIO4, rt; (10) 2,4,6-trichloro-benzoylchloride, Et3N, DMAP,
CH2Cl2, rt; (11) HF¨pyridine, CH3CN, rt; (12) Amberlyst-15 resin, CH2Cl2, rt; (13) Pd(OH)2, H2,
EtOAc, 1 atm; (b) (1) 10 mol % of [CpRu(CH3CN)3]PF6, acetone, rt; (2) NBS, DMF then BF3-OEt2,
1,3-propanedithiol, CH2Cl2, 0 ˝C then PPTS, CH3OH, CH(OCH3)3, refux; (3) TESCl, DMAP, then
pyridine, Ac2O; PPTS, MeOH, rt; DMSO, (COCl)2, Et3N, CH2Cl2 ´78 ˝C; Ph3PCH3Br, n-BuLi;
(4) TBAF, THF, rt; Me3SnOH, DCE, 140 ˝C, microwave; Pd(PPh3)4, CO, DMF/CH3OH, 85 ˝C;
TESOTf, 2,6-lutidine, CH2Cl2; (c) (1) n-BuLi, methyl propionate, BF3¨OEt2, THF, ´78 ˝C; (2) Pd(OAc)2,
tris(2,6-dimethoxyphenyl) phosphine, benzene, then Pd(O2CCF3)2, rt; (3) trifluoroperacetic acid,
NaHPO4, CH2Cl2/CH3CN/ CH3OH, 0 ˝C; Dess-Martin oxidation; NaBH4, CeCl3¨ 7H2O, ´30 ˝C;
Ac2O, pyridine, DMAP, CH2Cl2, rt; (4) CrCl2, CHI3, THF, rt; 26% (47% BRSM); Pd(PPh3)4, THF, rt;
(5) AcOH/H2O; (6) TESCl, ETA, DMF, ´35 to ´15 ˝C; (7) Et3N, DMAP, 2-mehyl-6-nitrobenzoic acid
anhydride, CH2Cl2; (8) benzene, 50–80 ˝C, 17 mol % of Grubbs-Hoveyda catalyst; (9) PPTS, MeOH, rt.
2.3.2. Discodermolide
Discodermolide (29, Figure 6) is a polyketide found in the marine sponge Discodermia dissoluta.
This marine product was reported to have a mechanism of action similar to that of taxol, i.e., by
blocking the cell cycle at G2/M checkpoint, and inducing apoptosis against several cancer cell lines
and against taxol-resistant cells.
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stereoselective diene hydroboration, and a strategy for alkylation of chiral enolate reaction was 
established through 36 steps with 13% yield [87]. 
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Figure 6. Structure of discodermolide (29) with highlighted subunits A, B, and C.
Biological activities of 29 include immunosuppressive properties, antiproliferative and antimitotic
properties, and was shown to be a potent inducer of accelerated cell senescence, a neuroprotective
agent, and to promote tubulin assembly [81–84]. In addition, 29 was also found to decrease the
MDR to taxol in paclitaxel-resistant colon carcinoma (SW60AD-300) and MDR ovarian carcinoma
(A2780Ad) [85].
The strategy to synthesize (+)-discodermolide (29) and its analogs was achieved by preparing the
three subunits: A (C-15–C-24), B (C-8–C-14), and C (C-1–C-7). The synthetic pathway was designed by
two key disconnection points at C-7–C-8 and C-14–C-15 with the two Z double bonds at C-8–C-9 and
C-13–C-14 being pivotal in this strategy. Formation of the C-7– -8 bond was envisaged through an
acetylide addition/reduction sequence, whereas formation of the C-14–C-15 linkage was accomplished
by a Pd-catalyzed C(sp2)-C(sp3) cross-coupling reaction [86]. Subunit B was prepared in two ain
stages: a crotyl-titanation reaction for the installation of the stereotriad and a dyotropic rearrangement
to build a Z-double bond I (Scheme 5a). The synthesis of subunit A started with the preparation
of the C-16–C-18 syn-syn stereotriad II, planned by means of a substrate-based crotylation reaction
under Keck’s conditions (Scheme 5b). The third building block, C-1–C-7 subunit C, incorporates
four stereocenters. The approach started with standard Brown crotylation of aldehyde to afford
syn-anti homoallylic alcohol III. Then, the α,β-unsaturated Weinreb amide was obtained through a
classical Horner-Wadsworth-E mons olefination. Finally, reaction of amide IV with benzaldehyde
yielded subunit C (Scheme 5c). The assembly of the three subunits by cross-coupling reaction and
deprotection were the last steps to afford 29. Recently, (+)-discodermolide (29) was synthesized by
catalytic stereoselective diene hydroboration, and a strategy for alkylation of chiral enolate reaction
was established through 36 steps with 13% yield [87].
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Scheme 5. Total synthesis of subunits A, B, and C of (+)-discodermolide (29). Reagents and conditions:
(a) (1) t-BuLi, Me2CuLi, LiCN, Et2O/DMS then n-Bu3SnCl; (2) TEMPO, BAIB; (b) (1) TBSOTf,
2,6-lutidine, O3, Sudan III then DMS; (2) TBSOTf, 2,6-lutidine; (3) Ni(acac)2, (CH2=CH4)Sn, MeLi;
(4) DDQ, CH2Cl2/H2O, I2, PPh3; (c) (1) TBSCl, imidazole, DIBAL-H, CH2Cl2, (COCl)2, DMSO; (2) O3,
Sudan III, (EtO)2P(O)CH2C(O)NMe, NaH; (3) PhCHO, KHMDS.
2.3.3. Halicondrin B and Derivatives
The macrolide halichondrin B (30, Figure 7), a polyether isolated from the marine sponge
Halichondria okadai, exhibited both in vitro and in vivo antitumor activity [88]. However, the
very limited availability impairs this marine natural product for its therapeutic application [89].
Eribulin mesylate (E7389, or Halaven®, 31), a synthetic analog of 30, was approved in 2010 by FDA for
the treatment of locally advanced and metastatic breast cancer by inhibiting the microtubules [89,90],
and was reported as a P-gp substrate [91]. The structure of 31 (Figure 7) is complex, containing several
oxygen heterocycles, two exocyclic meth lene groups, a k tal group, and a pyran ring with trans
ring junctio , along with 15 st reogenic centers. S veral molecular modifications of 31 have been
performed, a d SAR studies with semi-synthetic analogs revealed that the substituent on C-32 of
31 plays an important role in the P-gp mediated drug efflux. The presence of an amine function
in the substituents on C-32 in the analogs 32–35 led to a low susceptibility to P-gp-mediated drug
efflux, and compounds 32–35 were active against MDR tumor cell line in vitro and in xenograft
modelsin vivo [43,91]. Furthermore, treatment with eribulin in pretreated metastatic breast cancer
patients was confirmed as feasible and safe for real-world patients [92].
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Different methods for the synthesis, to obtain milligram to gram amounts of 31 have been
reported [75,93]. Generally, the synthetic pathway of 31 consists of preparation of two fragments, i.e.,
C-1–C-13 and C-14–C-26, as described by Kishi’s group in 1992, and one key fragment (C-27 to C-35).
The final assembly strategy is accomplished by the coupling reaction depicted in Scheme 6 [90,93].
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2.4. Alkaloids
2.4.1. Lamellarins and Derivatives
Lam llarins are a group of polycyclic pyrrole-c ntaining alkaloids possessing a common
14-phenyl-6H-[1]-benzopyrano[4’,3’,3,5]pyrrolo-[2,1-α]isoquinoline ring system [94]. Lamellarins were
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isolated from many marine organisms such as a prosobranch mollusk (Lamellaria sp.) [35,95], an
ascidian (Daphniphyllum chartaceum), a sponge (Dendrilla cactos), and unidentified ascidians [35].
More than 50 lamellarins have been described and mainly differ in the number and position of hydroxyl
and methoxy groups on the common chromenoindoles I scaffold (Figure 8) [96]. Some lamellarins
possess interesting biological activities e.g., lamellarin L (36) which exhibits cytotoxicity against P388
and A549 cancer cell lines [97], lamellarin D (37) which is also an inhibitor of topoisomerase I-targeted
antitumor agents and an antiproliferative agent [96,98] and the immunomodulating lamellarin α-20
sulfate which inhibits also HIV [99]. Lamellarin I (38) was the most potent polycyclic pyrrole-containing
alkaloid described as a MDR modulator. Methoxy-derivatives of lamellarin D (37), lamellarin K (39),
and lamellarin N (40) (Figure 8), exhibit not only potent cytotoxicity against MDR cancer cell lines,
but also reverse their MDR at non-cytotoxic concentration [100,101]. Compound 38 was 16 folds more
sensitive than verapamil in doxorubicin-resistant Lo Vo/Dx cell line, and it increased the cytotoxicity
of doxorubin, vinblastine, and daunorubicine in MDR cells because it directly inhibited P-gp pump
function and increased drug accumulation in the cells [102]. Lamellarin O (41) is relevant as a multiple
P-gp, BCRP, and MRP1 inhibitor [96], but synthetic analogs of 41, designed by QSAR studies and
incorporating the methoxyacetophenone moiety unit, did not show BCRP inhibitory activity [103].
This study also allowed to establish some SAR features: bromo or mono-/dimethyl substituents on the
indole moiety (Aryl-R2) in lamellarin O (41) lead to a decrease in the BCRP inhibitory activity [103]
(Figure 8).
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The structures of lamellarins are categorized into three types (Figure 8)—type I-a (lamellarin D,
37), type I-b (lamellarin L, 36), and type II [lamellarins O (41), R (42), Q (43)]. The syntheses of these
derivatives are illustrated by type as presented in the next subsections.
A total synthesis of a type-II lamellarins was described by Furstner in 1995. It was the first
characterized pathway by a non-fused pyrrole moiety. The synthetic pathways started with the
Sheffer-Weitz-epoxidation of an enone I, as depicted in Scheme 7a, followed by a Lewis acid-mediated
rearrangement and condensation with hydroxylamine to afford the corresponding isoxazole II.
Cleavage of the N-O bond, condensation, and McMurry cyclization were the subsequent steps to yield
lamellarin O dimethyl ester (Scheme 7a) [104]. Another alternative for type-II lamellarin synthesis was
performed by cross-coupling using the Stille, Suzuki or Negishi methods, as described by Banwell et al.
in 1997. In this process, the pyrrole was protected to form an intermediate which was suitable to afford
dibromopyrrole 2-carboxylate. N-desilylation and cross-coupling with aryl stannane produced the
coupling product which was subjected to N-alkylation, followed by desilylation to provide 41 with
high yield of 45% in six steps (Scheme 7b) [105]. The Banwell strategy was employed by Alvarez et al.
with variations on solid phase chemistry and gave lamellarin 43 (in 13% yield), and lamellarin 41
which could not be isolated [106]. In 2008, Iwao et al. used Banwell’s Suzuki-Miyaura cross-coupling
approach to synthesize type II lamellarins, yielding compounds 43, 41, and lamellarin P (44) in 7, 11,
and 12% respectively, over eight steps [107]. Therefore, increasing the steps of reaction did not increase
the reaction yield. Boger et al. described the synthesis of lamellarin 41 using an azadiene Diels-Alder
reaction named as 1,2,4,5-tetrazine-1,2-diazine-pyrrole transformation with the overall yield of 34%
within seven steps [108]. The pyrrole moiety was assembled by a [4+2] cycloaddition/cycloreversion
reaction, followed by a reductive ring transformation. They started by forming the acetylenic precursor
using Sonogashira-coupling from aryl acetylene and aryl iodide, followed by the cycloaddition of this
precursor to give 1,2-diazine which was then subjected to a reductive ring contraction and N-alkylation.
Selective hydrolysis of the symmetrical diester provided the monoacid. The subsequent hydrogenolysis
afforded lamellarin 41 (Scheme 7c) [108]. In 2012, Vazquez et al. used the Paal-Knorr pyrrole synthesis
to synthesize 41 in 25% yield in seven steps, and 43 in 28% yield in six steps [94].
The syntheses of lamellarins type I-a were performed via different approaches such as the
halogenation and cross-coupling reaction, N-ylide-mediated pyrrole ring formation, and other
miscellaneous approaches. Lamellarin D (37) was synthesized by Alverz et al. [109], starting from
the pyrrole ester. The A and B subunits of 37 were established by N-alkylation of pyrrole ester by
Baeyer-Villiger oxidation, palladium-catalyzed Heck-type cyclization, followed by a regioselective
bromination, providing the tricyclic building block which was subjected to Suzuki-Miyaura
cross-coupling sequence O-isopropylation of the phenolic group and to a second bromination-Suzuki
cross-coupling sequence. Introduction of a 5,6-double bond was accomplished by oxidation.
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p-MeO-C6H4COCH2Br, K2CO3, acetone, reflux; (b) (1) NBS (3 eq), THF; (2) PhLi (1 eq), then ClCO2Me
(1.05 eq); (3) Pd(PPh3)2Cl2 (10 mol%), 1,4-dioxane, p-TBOMSO-C4H6-SnMe3 (2 eq); (4) Bu4NF (1.1 eq),
THF, then 0.5 M HCl; (5) Bu4NF (1.1 eq), THF then 0.5 M HCl; (6) PPd(PPh3)2Cl2 (10 mol %), 1,4-dioxane,
p-TBOMSO-C4H6-SnMe3 (2 eq); (7) p-MeO-C4H6-COBr (3 eq), K2CO3 (5 eq), Bu4NCl (20 mol %), THF;
(8) Bu4NF (1.1 eq), THF, then 0.5 M HCl; (c) (1) Pd(PP3)2Cl2 (3 mol %), CuI (6 mol %), Et3N; (2) dimethyl
1,2,4,5-tetrazine-3,6-dicarboxylate, toluene, reflux; (3) Zn, HOAc; (4) p-MeO-C4H6-COBr, K2CO3, DMF;
(5) LiOH, THF/CH3OH/H2O (3:2:1); (6) TFA, CH2Cl2; (7) H2,Pd/C (0.1 wt %), EtOH.
Finally, cleavage of isopropyl esters, followed by acidic lactonization, afforded 37 in 3% yield,
over 16 steps (simplified in Scheme 8a) [109]. In the same year, Pla et al. reported a sequential
and regioselective bromination/Suzuki cross-coupling reaction to introduce the aryl group at
position 1 of methyl 5,6-dihydropyrrolo[2,1-a]isoquinoline-2-carboylate, with the combination of
microwave-assisted 2,3-dichloro-5,6-dicynobenzoquinone (DDQ) oxidation, followed by phenol
deprotection and lactonization to give 37 in the 18% yield in 8 steps reaction [109]. Iwao et al.
also reported the synthesis of 36, 37, and 40 in 19%, 18%, and 16% yields over 11, 12, and 12 steps,
respectively. They started from isopropyl-protected isovanillin and applied a nitroaldol condensation,
a N-dialkylation and Hinsberg pyrrole cyclization reactions (Scheme 8b) [110].
In 2001, Diaz et al. [101] constructed the pyrrole core in [3 + 2]-cycloaddition of nitrone to
synthesize 38 and 39 (Scheme 9).
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Reagents and conditions: (1) NaBH4, MeOH, H2O2, Na2WO3, MeOH; (2) toluene, 120 ˝C, 18 h; (3) AlCl3.
The N-oxides were prepared in mod rate yields by reduction of 3,4-dihydro-1-benzylisoquinolines,
followed by disodium tungstate-catalyzed oxidati n with hy rogen peroxide. Reaction of N-oxide
with alkyne produced an inter ediate through the 1,3-dipolar cycloaddition-thermal rearrangement.
Selective isopropyl group removal from the intermediate, with concomitant lactonization, gave
lamellarins 38 and 39 in 4 and 6% yields, respectively [101]. In 2014, Yamaguchi et al. reported
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the synthesis of lamellarin I (38) using β-selective arylation of pyrroles with aryl iodides and
a new double C-H/C-H coupling as a key step to afford 38 in 3% over 8 steps, starting from
2,3,4-trimethoxybenzaldehyde [111].
2.4.2. Ningalins and Derivatives
Ningalins are members of 3,4-dihydroxyphenyalanine (DOPA)-derived o-catechol metabolites
including the tunichromes [112]. Biological activities of ningalins include HIV-1 integrase
inhibition [113], Ningalin B (45, Figure 9), was isolated from an ascidian of the genus Didemnun
by Boger et al. in 1999. Compound 45 lacks of an intrinsic cytotoxicity which makes this alkaloid
an interesting model as MDR reversal agent. Interestingly, the synthetic analogs 46–50 were shown
to significantly sensitize the HCT116/VM46 human colorectal carcinoma cell overexpressing P-gp
to vinblastine and doxorubicin better than the marine natural product 45 and verapamil [114].
Studies of the N-aryl homologs of 45 (50–51) revealed that increasing the carbon linker leads
to increase in activity. The authors concluded that the N-alkylaryl substituent is necessary for
activity, but the analogs which bear free phenolic groups and methyl esters are more cytotoxic
and lack potent MDR reversal properties. Analogs of 45 containing tetra- or pentasubstituted
pyrroles showed the highest activity as MDR reversal agents [114–116] whereas those having
2-carboxylate or 2,5-carboxylates bearing 3,4-diaryl-substituted pyrroles showed reversal ability
toward HCT116/VM46 cells. Compound 51 exhibited the greatest potential in reversing the MDR at 1
µM, and at 10 µM with about a 4000-fold increase in sensitivity against the vinblastine resistant
MDR-leukemia cell line. This compound was also shown to compete with [3H]-azidopine for
P-gp binding site and increased the intracellular accumulation and retention of MDR substrates.
In nude mice-xenograft models, the combination of sub-optimal dose of paclitaxel with 51 not
only leads to shrinkage the HCT116 tumor size but also to a complete therapeutic remission
without increasing toxicity toward the host [116]. The analog 48 showed little or no effect of
MDR on HCT116/VM46. The amide analogs of 48 enhanced the MDR activity, while amine
derivatives (dimers) were inactive as MDR reversal compounds [115]. The synthetic analog of 46,
1-[2-(4-methoxyphenyl)-2-oxoetyl]-3,4-bis(3,4-dimethoxyphenyl)-1H-pyrrole-2,5-dione (52) which was
designed from permethyl ningalin B showed a remarkable enhancement of MDR reversal abilities
in concentrations up to 1 µM [117,118]. Compound 53, having a methoxy group on the D-ring,
showed a 18.2-fold increase in cell sensitization towards paclitaxel at 1 µM concentration, and a 66
fold one when 0.5 µM of 53 was combined with 0.5 µM of 54 [117]. It was found that increasing
the number of methoxy groups on ring B of the ningalin scaffold showed only low to moderate
P-gp-modulating activity, while the addition of a benzyloxy group on the D ring enhanced the P-gp
modulating activity [119]. SAR studies of a series of novel N-substituted derivatives of 45 on breast
P-gp-overexpressing tumor cell line (LCC6MDR) showed that analogs containing one methoxy group
and one benzyloxy group on ring C are the most potent P-gp modulators (1 µM desensitized cell line
by 42.7 folds) without showing cytotoxicity IC50 for L929 fibroblast >100 µM) [117,119,120]. The analog
55 containing dimethoxy groups on rings A and B, and trisubstitution with o-methoxyethylmorpholine,
m-bromo and p-benzyloxyl on ring D showed an effect compatible with P-gp modulation with an
effective concentration (EC50) of 423 µM in reversing paclitaxel resistance [118]. Figure 9 summarizes
the SAR established for this class of compounds against P-gp modulation highlighting the most
promising ningalin derivatives.
The synthesis of ningalin B (45) was described by Boger et al. using the Diels-Alder reaction of
the acetylene I with 1,2,4,5-tetrazine II to give the 1,2-diazine III. The synthetic pathway includes
the transformation of 1,2-diazine III to the pyrrole IV, followed by N-alkylation, lactonization and
decarboxylation, and demethylation to yield 45 (Scheme 10a) [121,122]. Another synthesis of ningalin B
(45) started from the aldehyde V and the amine VI, as depicted in Scheme 10b, and was accomplished
by oxidative coupling reaction to yield the pyrrole moiety, followed by Vilsmeier-Haack formylation
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under traditional heating to give the formylpyrrole VII which was subsequently converted to the
lactone and then to ningalin B (45) [113].Molecules 2016, 21, 892 20 of 50 
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N-methylwelwitindolinone (56) were found to have potent biological activities including antifungal, 
larvicidal, and insecticidal properties [124]. Most welwitindolinones possess a densely functionalized 
oxindole-fused bicyclo[4,3,1]decane ring system (Figure 10). The core structure of these alkaloids 
contains two contiguous stereogenic centers. These alkaloids exhibit a significant activity in reversing 
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and daunomycin in MDR breast carcinoma cell line. The absence of the N-methyl group reduced the 
Scheme 10. Synthesis of ningalin B (45). Reagents and conditions: (a) (1) N2; (2) Zn, AcOH; (3) K2CO3;
(b) (1) AgOAc, NaOAc, THF; (2) POCl3, DMF; (3) DMSO/H2O or THF: t-BuOH:H2O; (4) Pb(OAc)4,
EtOAc; (5) BBr3, CH2Cl2.
2.4.3. Welwitindolinones and Derivatives
Welwitindolinones are alkaloids found in the cyanobacteria Hapalosiphon weltischii, Westiella
intracta, Fischerella muscicola, and F. major [123,124]. The extracts which significantly contain
N-methylwelwitindolinone (56) were found to have potent biological activities including antifungal,
larvicidal, and insecticidal properties [124]. Most welwitindolinones possess a densely functionalized
oxindole-fused bicyclo[4,3,1]decane ring system (Figure 10). The core structure of these alkaloids
contains two co tiguous stereogenic centers. These alkaloids exhibit a significant activity in reversing
P-gp-medi ted drug resistance in huma tumor cells [125]. Among them, N-methylwelwitindolinone
C (56) enhanced cytotoxicity of anticancer drugs like vinblastine, taxol, actinomycin D, colchicine,
and daunomycin in MDR breast carcinoma cell line. The absence of the N-methyl group reduced
the activity, while the absence of the isothiocyanate group completely abolished the activity, as
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observed for welwitindolinone C isothiocyanate (57) and welwitindolinone isonitrile (58), respectively.
Welwitindolinone 57 was found to be the most potent derivative in increasing the accumulation of
[3H]-vinblastine and [3H]-paclitaxel by blocking P-gp in SK-VLB-1 cells. This compound also inhibits
the P-gp photoaffinity labeling by [3H]-azidopine in MDR cells [36].
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activity by inhibiting BCRP in a BCRP overexpressing breast cancer cell line (MDA-MB-123) and by 
reducing the resistance of mitoxantrone and camptothecin mediated by BCRP, but did not inhibit  
MDR-1 overexpressing cells growth [135]. More detailed studies of 59 revealed that this compound 
failed clinical in applications due to its low pharmacological effects and neurotoxicity [132,134]. To 
improve the therapeutic efficacy of 59, several derivatives were synthesized by modification of 
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Compound 57 was syn esized by t o different approaches—Gang’s and Rawal’s. In Gang’s
method, the synthetic pathway begins with coupling of a functional cyclohexanone using iodine
promoted bromoindole addition, followed by ring closure to form the key intermediate compound I.
Thereafter, 57 was formed by chlorination through vinyltrimethylstannane oxidation to oxindole,
isotopically enhanced tethered nitrene insertion, and isothiocyanate introduction (Scheme 11a) [126–128].
In Rawal’s approach (Scheme 11b), the coupling of silylenolether II with nucleophile bromoindole III
was achieved by Lewis acid to form the corresponding cyclohexanone IV which then produces the key
interme iate V by palladiu -catalyzed enolate rylation [124,129]. The key intermediate compound
V was subjected to aldehyde reduction via a hydrazine (oxidation to the oxindole), alcohol oxidation
and oxime for ation, and Curtius rearrangement of oxime to isothiocynate to furnish 57.
2.4.4. Harmine and Derivatives
Harmine (59) is a β-carboline alkaloid found in plants, mammalians, insects, and marine
organisms [130], e.g., the marine brown alga Melanothamnus afaqhusainii [131,132]. The plant
extracts containing 59 were traditionally used to treat alimentary tract cancer and malaria in
Northwest China [133]. These extracts have a broad spectrum of biological activities, including
antimicrobial, antifungal, antitumor, antiplasmodial, antioxidant, antimutagenic, antigenotoxic, as
well as hallucinogenic properties [130]. Compound 59 also inhibits topoisomerase I, cyclin-dependent
kinases, monoamine oxidase A, and intercalates int DNA [134]. Studies on the biological function
of 59 reported this alkaloid as a potent antiprolif rative and cytotoxic gent, with MDR reversal
activity by inhibiting BCRP in a BCRP overexpressing breast cancer cell line (MDA-MB-123) and by
reducing the resistance of mitoxantrone and camptothecin mediated by BCRP, but did not inhibit
MDR-1 overexpressing cells growth [135]. More detailed studies of 59 revealed that this compound
failed clinical in applications due to its low pharmacological effects and neurotoxicity [132,134].
To improve the therapeutic efficacy of 59, several derivatives were synthesized by modification
of substituents in positions 2, 7, and 9 of harmine (59) ring and with other two different
groups—2-amino-2-deoxy-D-glucose and methionine—two derivatives were obtained, 2DG-Har-01
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(60) and MET-Har-02 (61), respectively. This study found that substitution at position 7 reduced
natural toxicity and increased tumor cell uptake ability, at position 9 enhanced cytotoxicity, and at
position 2 enhanced the antiproliferative effect [132], and also showed that substituents at position
1 could be crucial to antitumor potency [136]. SAR studies confirmed that substituents in position
2 and 9 displayed an important role in modulation of antitumor activities [134]. Derivatives of 59 that
possess in R1, R2, and, R3 (Figure 11) a benzyl and 3’-fluorobenzyl groups are more likely to act as
protein synthesis inhibitors [137].
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Scheme 11. Synthesis of N-methylwelwitindolinone C isothiocyanate (57) by Gang’s approach (a) and
Rawal’s approach (b). Reagents and conditions: (a) (1) iodine promoted bromination; (2) NaNH2, t-BuOH,
THF; (3) trimethyethylstannane; (4) LiEt3B-D, THF, Cl3CCONCO, CH2Cl2, K2CO3, MeOH; AgOTf,
PhI(OAc)2, CH3CN, bathophenantroline; (5) NaH, air, THF; (b) (1) TiCl4, toluene; (2) Pd(OAc)2, P-tBu3,
KO-tBu, toluene; (3) NaBH(OMe)3, THF/EtOH then N2H2, AcOH, EtOH; NCS, pyridine; MMPP, TFA,
AcOH; (4) Dess-Martin periodinane, NaHCO3, CH2Cl2; NH2OH.HCl, pyridine, MeOH; (5) NCS, DMF,
THF, then Et3N.
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Figure 11. Harmine (59) and analogs 60–62. The dashed circles indicate groups important for
biological functions.
The scaffold of harmine (59, β-carboline) was a model for the synthesis of novel compounds
which are bivalent β-carbolines. The different number of methylene units in the linker between
two β-carbolines produced agents which displayed good and selective cytotoxicity against 769-P and
KB cell lines, being the six methylene unit derivative 62 a potent antitumor compound against Lewis
lung cancer in mice [136].
The synthesis of β-carboline-based alkaloids has been reported using tryptophan as starting
material [138,139]. To the best of our knowledge, there is no report on the total synthesis of 59. Most of
the harmine analogs were synthesized from the harmine scaffold using the Friedel-Crafts reaction,
molecular modifications, a N-oxidation [132,140–142].
2.4.5. Indolcarbazoles and Derivatives
Indolcarbazoles are alkaloids isolated from marine-derived actinomycetes strain Z039-2 which
possess a broad spectrum of biological activities including anticancer activity [143]. The mechanisms
of their antitumor effects include topoisomerase I poisoning, inhibition of PKC, PKA, pyruvate
dehydrogenase kinase (PDK)/cyclin B, and cyclin-dependent kinase 5 (CDK5)/p5 [144,145].
The naturally occurring arcyriaflavin (63) and indolcarbazole K252c or staurosporin aglycone (64,
Figure 12) showed the most potent effects in BCRP inhibition in the BCRP-transferred HEK-293 cell line,
with low toxicity in BCRP-tran fected cells, and reduced the relative resistance of ABCG2-transfected
cells SN-38 [29,146]. Bisindol lmaleimide analogs 65–69 (Figure 12) were found to be able to inhibit
[125I]iodoarylazidoprazosin labeling of BCRP by 65% to 80% at 20 µM [146]. Thes findings re aled
that indolocarbazole and bisindolylmaleimide analogs directly interact with BCRP protein and may
increase oral bioavailability of BCRP substrates.
The indolocabazole nucleus was prepared from bis-indolylmaleimides, followed an oxidative
cyclisation to give the indolocarbazole (Scheme 12a). Another way to obtain the indolocarbazole
nucleus was applied in the preparation of N-methyl indolocarbazole (70) which was obtained from
N-methylpyrrole by bromination and oxidation to give N-methyldibromomaleimide which was
coupled with indolylmagnesium bromide to afford bis-indolylmaleimide. Oxidative cyclization of the
later compound led to indolocarbazole 70, as depicted in Scheme 12b [145,147,148].
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Scheme 12. Synthesis of indolcarbazole derivatives 63 and 70. Reagents and conditions: (a) (1) i. EtMgBr,
THF, benzene, ii. N-methylmaleimide; (2) KOH, MeOH or dioxane; (3) NH4OAc; (4) DDQ, PTSA,
toluene; (b) (1) Br2, HNO3; (2) CH3CH2Br, Mg, THF, indole, toluene; (3) DDQ, toluene.
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2.4.6. Ecteinascidin 743 (Trabectedin) and Derivatives
Esteinascidin 743 or trabectedin (71, Figure 13) is an anticancer tetrahydroisoquinolone alkaloid
already approved by the FDA. This compound was first isolated from the Caribbean tunicate
Ecteinascidia turbinata in a minute quantity. However, this compound could be synthesized from
cyanosafracin B, a starting material obtained from fermentation of Pseudomonas fluorescens [149]. It is
a highly potent anticancer agent and has activity against a number of human solid tumor cells. The
compound was also showed to reverse the resistance to doxorubicin and vincristine in KB-C2 and
KB-8-5 cells overexpressing P-gp in concentrations of 0.1 nM [150,151]. Trabectedin (71) was approved
as the medicine Yondelis® for the treatment of advanced soft-tissue sarcomas and ovarian cancer.
Although 71 is a substrate for P-gp, this potential mechanism of resistance has only been shown to be
significant at concentrations exceeding clinically relevant values [151]. Moreover, this marine natural
product also inhibits the activation of the MDR-1 gene that encodes for P-gp [152]. Therefore, 71 could
be considered a promising model to overcome MDR. For instance, the synthetic agent lurbinectedin or
PM01183 (72), which was obtained by modification of the subunit C of 71, showed a potent cytotoxic
activity against tumor cell line of different origin, and it was introduced in phase I clinical trials for
solid tumor, and phase II for metastatic pancreatic cancer. PM01183 (72) showed enhanced activity
to cisplatin- and oxaliplatin-resistant cell line, and combination of 72 and cisplatin was the most
synergistic toward parental and cisplatin-resistant ovarian carcinoma cells [153].
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Syntheses of trabectedin (71) have been described by many researchers. In summary, there
are three important pathways (Scheme 13): (A) combination of two fragments (I a d II) via an
oxazolidine i termediat , (B) acid-promoted macrocyclization via creation of carbon-sulfur bond with
concomitant forma ion o a 10-memb red ring, a d (C) the intramolecular Pictet-Spen ler reaction
to obtain 71 [154–157]. The straightforward synthesis of 71, using 28 steps with 1.1% yield, started
from L-glutamic acid as the single chiral source [158] while a 31 steps synthesis, with 1.7% yield,
began from 3-methylcatechol [159]. The first conditions lead to the B-ring formation by stereoselective
Heck reaction between diazonium salt and enamide, oxidative cleavage of the resulting alkane and
intramolecular ortho substitution of phenol by aldehyde. This pathway can form a diketopiperazine by
Perkin condensation and the bicyclo[3.3.3]system by an N-acyliminium ion-mediated cyclization, and
a regioselective Suzuki-Miyaura coupling (Scheme 13) [158]. In 2000, Cuevas et al. [149] established
the synth sis of 71 and 72 from cyanosafracin B, which is an ntibi tic ob ained from fermentation of
the bacterium Pse d monas fluorescens. The methoxy-p-quinone of cyanosafracin B was tr ated with
bromochloromethane, followed by Edman degradation to form thiourea (Scheme 13). The critical
substitution of the amino group by an alcohol group gave the key intermediate to yield 71 through the
Corey method [149].
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Scheme 13. Total synthesis of trabectedin (71). Reagents and conditions: (1) PhI(OAc)2, MeOH; (2) NaCN,
DMF/H2O; (3) BnBr, K2CO3, DMF; (4) aq H2O2, K2CO3, DMSO; (5) PhI(OAc)2, KOH, MeOH; (6) LiOH,
EtOH/H2O, reflux; (7) t-BuOK, THF, DBU, (8) Boc2O, DMAP, THF, (2 steps); (9) H2 (750 psi), Pd/C,
EtOAc; (10) H2NNH2¨H2O, THF, evaporation; NaBH4, MeOH, (2 steps); (11) TFA, CF3CH2OH;
evaporation; PhNTf2, DMAP, Cs2CO3, MeCN; (12) trimethylboroxine, Pd(PPh3)4, K3PO4, 1,4-dioxane;
(13) HCl, EtOAc; ClCO2Me, NaHCO3, H2O; (14) L-Selectride, THF; (15) CSA, toluene, reflux (2 steps);
(16) aq KOH, 1,4-dioxane, rt, MOMCl.
2.5. Diketopiperazines
2.5.1. Nocardioazines
Nocardioazines are bridged diketopiperazine alkaloids which were isolated from a non-saline
liquid culture of Nocardiopsis sp. (CMB-M0232). Nocardioazine A (73) is composed of cyclo-(L-Trp-
L-Trp) and cyclo-(L-Trp-D-Trp), as shown in Figure 14. This compound has revealed an effect compatible
with P-gp inhibition in a P-gp overexpressing colon cancer cell line (SW60Ad300) [160].
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Figure 14. Structure of nocardioazine A (73).
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The first synthesis of (+)-nocardioazine A (73) was reported in 2014 by Wang and Reisman.
The synthetic pathway comprises the building of the pyrroloindoline unit from an enantioselective
formal [3 + 2] cycloaddition, and an unusual intramolecular diketopiperazine formation. The synthesis
was performed from 3-allylindole in nine steps which gave an overall yield of 11% of 73
(Scheme 14) [161].
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activity (Figure 15) [167]. Unfortunately, 74 was found to induce tremors or convulsion in mice and 
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Scheme 14. Total synthesis of nocardioazine A (73). Reagents and conditions: (1) (S)-BINOL, SnCl4,
DCM; (2) OiPr-HG II, DCM, reflux; (3) NaBH4, CeCl3¨ 7H2O, MeOH; (4) (+)-diethyl tartrate, Ti(OiPr)4,
tBuOOH, 4Å MS, DMC; (5) MsCl, Et3N, THF; (6) TBAI, DIPEA, CH3CN; (7) Pd2(dba)3, dppb, DMBA,
DEC; (8) LiOH, THF/H2O; (9) PyBrop, DIPEA, DMF.
2.5.2. Fumitremorgins and Derivatives
Fumi r morgin C (FTC, 74) is an indolyl diketopiperaz ne alkaloid found in several marine
fungi such as the fungal strain BM939, fu gal A-f-11, Aspergillus sydowii, and Asp rgillus fumigatus
(YK-7) [162]. Fumitremorgins were found to be tremorgenic mycotoxins by interfering th releasing
neurotransmitters and also showed inhibitory activity on cell cycle [163]. Com ound 74 was reported
as a chemosensitizing agent that could reverse a drug-resistant cell lines that do not overexpress
P-gp and MRP [163,164]. This effect was shown to be due to BCRP expression in the S1-M1-3.2
cell line resistant to mitoxantrone, topotecan, and doxorubicin [164]. Fumitremorgin C (74) almost
completely reversed resistance mediated by BCRP in MCF-7 cells transfected with this protein [165].
Moreover, 75 was found to inhibit nitrofurantoin and mitoxantrone (BCRP’s substrates) transcellular
transport in MDCKII and MEF3.8 cell lines [166]. The SAR study using the ftm gene cluster revealed
that the moieties that are essential for inhibitory activity of 74 against BCRP are the double bond
between C-3 and N-4, as well as the methoxy group at C-18, however, the hydroxyl groups at C-12
and C-13 lead to a decrease in activity (Figure 15) [167]. Unfortunately, 74 was found to induce
tremors or convulsion in mice and other animals [168]. Two derivatives, Ko132 (75) and Ko134
(76), were found to be potent inhibitors of the BCRP-mediated drug efflux in T6400 mouse and T8
human cell lines with low cytotoxicity at an effective concentration of 1 µM [163,169]. In addition,
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77 was the most effective inhibitor of BCRP, with very low activity against P-gp or other known
drug transporters [168,170]. In addition, the stereospecificity was shown to be very critical in the Ko
family, for example, compounds having the 3S,6S,12αS configuration were 18 times more potent than
those with 3S,6R,12αS configuration in inhibiting BCRP; however, this stereoselective effect was not
observed in P-gp and MRP-1 [171].
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Figure 15. Structures of fumitremorgin C (74) and derivatives 75–78 and SAR for BCRP inhibition.
The first synthesis of 74 was reported by Hino et al. who pr pared N-propyl-7-methoxy-β-carboline
as the key n e mediate [172]. Loevezijn et al. reported a solid phase synth si of demethoxy-FTC
(78), also an inhibitor of BCRP-medi ted MDR, by a cycliz ti /cleavag multiple parallel syntheses
method (Scheme 15a). This synthetic pathway was based on the formation of the diketopiperazine
rings system, followed by simultaneous cleavage of solid support, which acted as a leaving group at the
cyclization step. The reaction was performed by the Pictet-Spengler condensation of the hydroxyethyl
functionalized polystyrene resin linked L-tryptophan with excess of aldehyde Scheme 15a [163,169].
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pyrrolidine (Scheme 15b) [173]. The synthesis of Ko143 (77), a potent BCRP inhibitor of the FTC series 
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Scheme 15. Total synthesis of FTC derivatives, dimethoxy-FTC (78) and Ko143 (77). Reagents
and conditions: (a) (1) CH(OMe)3; (2) Fmoc-HCl, pyridine, CH2Cl2; (3) piperidine, DMF;
(4) Fmoc-L-pro-OH, CIP, DiPEA, MNP; (5) piperidine, THF; (b) (1) Hg(OOCCF3)2, KI, I2,
CH2Cl2, the Boc2O, DMAP, MeCN; (2) Pd(OAc)2, Ag2CO3, toluene; (3) Mg(ClO4)2, MeCN;
(c) (1) 1-benzyl-2-methyl-(S)-1,2-aziridinedicarboxylate, ytterbium triflate, CH2Cl2; (2) H2 balloon,
MeOH, 10% Pd/C; (3) isovaleraldehyde, TFA, CH2Cl2; (4) N-Fmoc-5-t-butyl L-glutamic
acid ester, diisopropylethylamine 2-chloro-1,3-dimethylimmidazolinium hexaflorophosphate,
N-methylpyrrolidinone; (5) piperidine, THF.
Another alternative to obtain 78 was achieved by Mg(ClO4)2-catalyzed intramolecular allylic
amination with carbamate or sulfonamide as nucleophiles to form substituted piperidine and
pyrrolidine (Scheme 15b) [173]. The synthesis of Ko143 (77), a potent BCRP inhibitor of the
FTC series w s accomplished and optimized by Yuexian et al. [174] which involved ytterbium
triflate-promoted coupling between 6-methoxyindole and optically active 1-benzyl-2-methyl-(S)-
1,2-aziridinedicarboxylate (Scheme 15c) [174].
2.5.3. Halimide and Derivatives
Halimide, is a diketopiperazine secondary metabolite isolated from the marine fungus
Aspergillus ustus. This compound exhibited potential in vitro cytotoxic activity against human colon
and ovaria carcinoma c lls [175]. Structurally, halimide is composed of a phenylala ine, a histidine,
and a tertiary butyl group. An analog of halimide, plinabulin (KPU-2, 79, Figure 16), that was
obtained by molecular modification at the phenyl ring, has revealed a potent in vitro antitumor
activity not only against various human tumor cell lines, but also against those with various MDR
profiles [176]. Moreover, 79 was reported to have a similar mechanism of action to that of eribulin
(31) as microtubule-disrupting agent with colchicine-like tubulin-depolymerizing activity, but the
main problem concerning 79 is its poor solubility (<0.1 µM), which can trigger further studies on this
scaffold. The phase I/II clinical trial of 79 in combination with docetaxel was completed in patients
with advanced non-small cell lung cancer, and compound 79 was shown to act synergistically with
docetaxel in murine models of NSCLC [177].
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At 20 µM concentration, compound 80 significantly enhanced the accumulation of [3H]-paclitaxel
in SKVLB1 cells, and exhibited a similar activity to verapamil in breast cancer cell MCF-7/ADR
in the range of 1.5–10 µM [180,181]. Several syntheses for 80 and its respective analogs have been
reported, with the purpose of obtai ing compounds wit similar or better MDR reversal activity.
Some of t e analogs did not fulfill this objective; for example, the glucose mimic of hapalosin (80)
and 8-deoxyhapalosin, the triamide analogs, and N-demethylhapalosin 81 possessing a trans-amide,
exhibited weak MDR reversal activity [180–182]. Through SAR studies, proline-containing congeners
(82 and 83) were found to be more potent against MCF-7/ADR cells than 81 [182]. Substitution at C-12
in 80 furnished analogs 84–88, which exhibited higher vincristine accumulation than verapamil and
80 in MDR 2780AD cells at 10 µM [183]. It was postu ated that the cis-peptide might be essential to
express the MDR-reversing activity, and the bioactive function of 80 and analogs depends on the S-cis
or S-trans configuration [182,184]. Also, a free hydroxyl and aromatic groups may be important for the
anti-MDR activity of hapalosin (80) and its analogs.
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The structure of hapalosin (80) was investigated for synthesis, and it was divided into
3 main domains: a β-hydroxy acid (A), a γ-amino-β-hydroxy acid (B), and an α-hydroxy acid
(C). Hapalosin (80) was initially synthesized by macrolactonization and by cycloamidation [185].
Nobuki et al. reported the synthesis of 80 and analogs by cyclization, producing the peptide
bond at the end of the process which allowed obtaining 80 in 44% yield. They used the coupling
of N-propionyl-(4S,5R)-4-methyl-5-phenyl-2-oxazolidinone with octanal (Scheme 16a) [181,186].
Another synthesis of hapalosin (80) and its analogs was accomplished by a macrolactonization
strategy [187–189]. The method was based on a chiral acetate reagent, which offered advantages
to the aldol reaction and avoided intramolecular cyclization during amino group deprotection and
segment coupling [189]. Shigeru et al. presented the synthesis of hapalosin (80) and derivatives with
modification at C-12 by cyclization producing the peptide bond at the final stage [183]. According to
their strategy, hapalosin (80) and derivatives were commenced by using γ-amino-β-hydroxy acid
I which was obtained by either Evans aldol/Curtius combination route [190] or asymmetric
dihydroxylation route [191].
Then, the catalytic hydrogenation of the benzyl ester II was performed, and the generated
carboxylic acid was coupled with an appropriate allyl α-hydroxylate, leading to allyl ester III.
After sequential deprotection, cyclization produced 80 and derivatives (Scheme 16b). Kumar et al. also
described a flexible and highly diastereoselective synthesis of hapalosin (80) with the addition of an
organometallic reagent to N-tert-butanesulfinylimine, the non-aldol aldol reaction, and the Yamaguchi
esterification as key steps in this strategy [192].
Molecules 2016, 21, 892 32 of 50 
 
The structure of hapalosi  (80) was investigated for synthesis, and it was divided into 3 main 
domains: a β-hydroxy acid (A), a γ-amin -β-hydroxy acid (B), a d an α-hydroxy acid (C). Hapalosin 
(80) was initially synthesized by macrolactonization and by cycloamidation [185]. Nobuki et al. 
reported the synthesis of 80 and analogs by cyclization, producing the peptide bond at the end of the 
process which allowed obtaining 80 in 44% yield. They used the coupling of N-propionyl-(4S,5R)-4-
methyl-5-phenyl-2-oxazolidinone with octanal (Scheme 16a) [181,186]. Another synthesis of hapalosin 
(80) and its analogs was accomplished by a macrolactonization strategy [187–189]. The method was 
based on a chiral acetate reagent, which offered advantages to the aldol reaction and avoided 
intramolecular cyclization during amino group deprotection and segment coupling [189]. Shigeru et 
al. presented the synthesis of hapalosin (80) and derivatives with modification at C-12 by cyclization 
producing the peptide bond at the final stage [183]. According to the r strategy, hapalosin (80) and 
derivatives were commenced by using γ-amino-β-hydroxy acid I which was obtained by either Evans 
aldol/Curtius combination route [190] or asymmetric dihydroxylation route [191]. 
Then, the catalytic hydrogenation of the benzyl ester II was performed, and the generated 
carboxylic acid was coupled with an appropriate allyl α-hydroxylate, leading to allyl ester III. After 
sequential deprotection, cyclization produced 80 and derivatives (Scheme 16b). Kumar et al. also 
described a flexible and highly diastereoselective synthesis of hapalosin (80) with the addition of an 
organometallic reagent to N-tert-butanesulfinylimine, the non-aldol aldol reaction, and the Yamaguchi 
esterification as key steps in this strategy [192]. 
 
Scheme 16. Synthesis of hapalosin (80) and derivatives. Reagents and conditions: (a) (1) Bu2BOTf, 
Et3N/CH2Cl2, then Me(CH2)6CHO; (2) n-BuLi, BnOH/THF; (3) Ref. [193]; (4) NaOH, DCC, DMAP/CH2Cl2; 
(5) H2, Pd(OH)2/EtOH, vinyl-2-hydroxy-3-methylbutanoate, DCC, DMAP/CH2Cl2; (6) TFA/CH2Cl2, 
DPPA, i-Pr2NEt/DMF; (b) (1) i. DCC, DMAP/CH2Cl2, ii. H2, Pd(OH)2/EtOH, (2) DCC, DMAP/CH2Cl2; 
(3) i. HF-pyridine, ii. (Ph3P)4Pd, morpholine, then TFA, iii. DPPA, EtNt-Pr. 
Scheme 16. Synthesis of hapalosin (80) and derivatives. Reagents and conditions: (a) (1) Bu2BOTf,
Et3N/CH2Cl2, then Me(CH2)6CHO; (2) n-BuLi, BnOH/THF; (3) Ref. [193]; (4) NaOH, DCC,
DMAP/CH2Cl2; (5) H2, Pd(OH)2/EtOH, vinyl-2-hydroxy-3-methylbutanoate, DCC, DMAP/CH2Cl2;
(6) TFA/CH2Cl2, DPPA, i-Pr2NEt/DMF; (b) (1) i. DCC, DMAP/CH2Cl2, ii. H2, Pd(OH)2/EtOH,
(2) DCC, DMAP/CH2Cl2; (3) i. HF-pyridine, ii. (Ph3P)4Pd, morpholine, then TFA, iii. DPPA, EtNt-Pr.
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2.6.2. Botryllamides and Derivatives
Botryllamides are a group of dehydrotyrosine derivatives, isolated from styelid ascidians
Botryllus sp. [194,195]. Some botryllamides exhibited weak cytotoxicity against the HCT-116 tumor
cells [195]. Botryllamides exhibited selectivity toward BCRP, but have different specificity to other
ABC transporters. Two naturally occurring botryllamides, botryllamide I (89) and J (90) were
reported to have activity against BCRP by inhibiting BCRP-mediated BODIPY FL prazosin
transport in BCRP-transfected HEK293 cells (Figure 18). Both 89 and 90 competed with
[125I]-iodoaryl-azidoprazosin labeling of BCRP, and were shown to stimulate BCRP-associated ATPase
activity, reversing BCRP-mediated resistance [196]. In a different study, botryllamide G (91) was
reported as the most potent botryllamide BCRP inhibitor, but did not inhibit the efflux of rhodamine
out of P-gp overexpressing cells. In contrast, botryllamide A (92), which is less potent against BCRP,
showed that activity against P-gp [197]. These differences were explained by the present or absent of an
o-methyl group at C-15. The biological investigation of analogs of botryllamides 92 and 93 suggested
that the 2-methoxy-p-coumaric acid moiety and the number of conjugated double bonds with this
group were important for BCRP inhibition [197]. This study also found that: (i) the phenolic hydroxyl
group at C-7 was not important for activity; (ii) the binding region with BCRP was between C-4 and
C-9 (right side of Figure 18) of the aryl ring; and (iii) conjugation through C-1 to C-9 was necessary for
activity, but extended conjugation from C-10 to C-17 (left side of Figure 18) of the aryl ring was not
required, however, it might contribute to specificity of activity.
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Figure 18. Botryllamides 89–93 studies on BCRP inhibitory activity.
The syntheses of botryllamides G (91) and F (93) were already described, and are depicted in
Scheme 17. The strategy started with a condensation of octopamine with 2-methoxy-p-coumaric acid
to generate an amide bond, followed by a dehydration of the adjacent hydroxyl group to provide the
key enamine amide functionality [197].
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Kendarimide A (94, Figure 19) is an oligopeptide found in the Indonesian sponge Haliclona sp. 
This compound showed the potential of MDR reversal in human carcinoma (KB-C2) cell line 
overexpressing P-gp at the concentration of 6 μM, however, it was not active against KB-3-1 at the 
same concentration. The combination of 94 (6 μM) with colchicine (0.1 μg/mL) was found to inhibit 
KB-C2 cell growth by 87% [198]. Kendarimide A (94) is composed of several amino acids such as  
N-methylpyroglutamic acid (pyroMeGlu), N-methylated eight membered cysteinyl-cysteine  
(ox-[MeCys-MeCys]) together with many N-methyl amino acid residues, similar to cyclosporine A, a 
well-known P-gp inhibitor [199]. These data highlight that peptides can be considered as a valuable 
scaffold to reverse MDR. 
 
Figure 19. Structure of kendarimide A (94). 
From our understanding the total synthesis of compound 94 has not yet been reported.  
L-pyroMeGlu-L-Phe-OEt is the moiety that was synthetized as a model compound to represent 
pyroMeGlu of 94 as described in Scheme 18a [198]. Another synthetic model compound (N-
Scheme 17. Synthesis of boryllamides G (91) and F (93). Reagents and conditions: (1) NaOMe, MeOH,
reflux, overnight; (2) octopamine¨HCl or bis-brominated octopamine, WSCl, HOBt, Et3N; (3) Ac2O,
pyridine; (4) K2CO3, DMSO.
2.6.3. Kendarimide
Kendarimide A (94, Figure 19) is an oligopeptide found in the Indonesian sponge Haliclona sp.
This compound showed the potential of MDR reversal in human carcinoma (KB-C2) cell line
overexpressing P-gp at the concentration of 6 µM, however, it was not active against KB-3-1 at
the same oncentration. The combination of 94 (6 µM) with c lchicine (0.1 µg/mL) wa found to
inhibit KB-C2 cell growth by 87% [198]. Kendari ide A (94) s composed of several amino acids
such as N-methylpyroglutamic ac d (pyroMeGlu), N- ethylated e ght me be ed cysteinyl-cysteine
(ox-[MeCys-MeCys]) toge her with many N-methyl amino acid residues, similar to cyclosporine A, a
well-kn wn P-gp inhibitor [199]. These data highlight that peptides can be considered as a valuable
scaffold to reverse MDR.
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pyroMeGlu of 94 as described in Scheme 18a [198]. Another synthetic model compound
(N-methylcysteinyl-N-methylcysteine ring) to study the absolute stereostructure of the C-terminal
tetrapeptides (N-MeCys-N-MeCys) in 94 was synthesized, and the absolute configuration of both of the
two adjacent N-methylcysteines in 94, which form an eight-membered disulfide ring, was elucidated
to be L. The synthetic pathway was described in Scheme 18b [199].
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Patellamides are thiazole and oxazoline lipophilic cyclic peptides isolated from the tunicate 
Lissoclinum patella. These compounds exhibited cytotoxicity and reversed MDR in tumor cells. 
Patellamides B (95), C (96), and D (97) showed reversal activity and enhanced the activity of P-gp 
inhibitors such as vinblastine, colchicine, and doxorubicin in CEM/VLB100 cell line (Figure 20) [200,201].  
Scheme 18. Synthesis of L-pyroMeGlu-L-Phe-OEt (a) and L,L-N-methylcysteinyl-N-methylcystein ring
(b). Reagents and Conditions: (a) (1) H2O, 132 ˝C, 1.9 kg/cm2 (autoclave); (2) Na2HCO3, C2H5I,
DMF; (3) TFA, CH2Cl2; (4) L-N-pyroMeGlu, DEPC, TEA, DMF, 0 ˝C; (b) (1) acetamidomethanol,
conc. HCl, (Boc)2O, 1N NaOH; (2) (Boc)2O, 1N NaOH, Ac2O, pyridine; (3) TFA, CH2Cl2; (4) DEPC,
Et3N, DMF; (5) TFA, CH2Cl2, quant.; (6) EDCI, HOAt, CH2Cl2/DMF; (7) I2, CH2Cl2/MeOH; (8) TFA,
CH2Cl2, qu nt.
2.6.4. Patellamide and Derivatives
Patellamides are thiazole and oxazoline lipophilic cyclic peptides isolated from the tunicate
Lissoclinum patella. These compounds exhibited cytotoxicity and reversed MDR in tumor cells.
Patellamides B (95), C (96), and D (97) showed reversal activity and enhanced the activity of P-gp inhibitors
such as vinblastine, colchicine, and doxorubicin in CEM/VLB100 cell line (Figure 20) [200,201].
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Scheme 19. Synthesis of patellamide A (98). Reagents and conditions: (1) 20% piperidine/DMF, HOBt, 
HBTU, DIEA, Fmoc-aThr(Trt)-OH; (2) 20% piperidine/DMF, HOBt, HBTU, DIEA, Fmoc-Ile-OH; (3) 
Pd(PPh3)4, PhSiH3, CH2Cl2, 6 h and 20% piperidine/DMF; (4) HOBt, HBTU, DIEA, CH2Cl2, 2% TFA, 
PhSH, CH2Cl2; (5) Burgess reagent, THF, 55 °C, 1 h then 77 °C, 4 h; (6) Pd(PPh3)4, PhSiH3, CH2Cl2, 2 h. 
Figure 20. Structures of patellamides B (95), C (96), and D (97).
P tellamide D (97) showed a better result than verapamil in modul ting drug resistance in vitro,
and colchicine cytotoxicit were enhance by 2.8 fold. Doxorubicin toxicity was reduced from IC50
> 1000 ng/mL to 110 ng/mL, by 97. This result indicated that patellamide D (97) acts as a selective
antagonist in MDR, and thus can be considered as a potential modulator for drug resistance [7].
The synthesis of patellamide derivatives has been accomplished, using thiazole as starting material, via
two contemporary heterocyclization approaches to form oxazolines and thiazoline via coupling and
cyclodehydration reactions. The example illustrating the synthesis of patellamide A (98) is described
in Scheme 19 [202].
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Scheme 19. Synthesis of patellamide A (98). Reagents and conditions: (1) 20% piperidine/DMF, HOBt,
HBTU, DIEA, Fmoc-aThr(Trt)-OH; (2) 20% piperidine/DMF, HOBt, HBTU, DIEA, Fmoc-Ile-OH;
(3) Pd(PPh3)4, PhSiH3, CH2Cl2, 6 h and 20% piperidine/DMF; (4) HOBt, HBTU, DIEA, CH2Cl2,
2% TFA, PhSH, CH2Cl2; (5) Burgess reagent, THF, 55 ˝C, 1 h then 77 ˝C, 4 h; (6) Pd(PPh3)4, PhSiH3,
CH2Cl2, 2 h.
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2.7. Miscellaneous
2.7.1. Irciniasulfonic Acid Derivatives
Irciniasulfonic acids consist of ISA (compounds 99–101, [203]) and ISA-B (compounds 102,
103, [204]). These acids are esters that were isolated from the marine sponge Ircinia sp. [203], and
deacyl irciniasulfonic acid was isolated from tropical Coscinoderma sp. sponge (Figure 21) [205].
Irciniasulfonic acids 99–103 were found to reverse MDR against KB/VJ300 overexpressing P-gp at the
concentration of 100 µM in the present of vincristine [203,204,206]. Compound 99–101 were shown to
reverse MDR against KB/VJ300 overexpressing P-pg in the presence of verapamil at the concentration
of 25 µM, and the simplified analog (deacyl ISA, 104) showed to be 13-fold more potent than other
irciniasulfonic acids in reversal the MDR phenotype [203,204].
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Figure 21. Structure of ISA (99–101), ISA-B (102, 103), and deacyl ISA (104).
The synthesis of ISA derivatives was accomplished using propylene oxide as starting material
via a convergent approach to achieve both enantiomers of the natural product and allowed also the
incorporation of a range of side chains for optimization of their biological activity. The procedure of
this synthesis is illustrated in Scheme 20 [207].
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Scheme 20. The total synthesis of ISA derivatives. Reagents and conditions: (1) n-BuLi, Et2AlCl,
toluene; (2) KH; (3) TBS-Cl, imidazole, DMAP, DMF; (4) n-BuLi, Boc2O; (5) CuBr2.SMe2, MeLi, THF;
(6) HF-pyridine; (7) TFA, CH2Cl2; (8) (COCl)2, DMF cat, CH2Cl2, toluene, reflux.
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2.7.2. Secalonic Acid D
Secalonic acid D (105, Scheme 21) is a mycotoxin isolated from the marine fungi
Penicillium oxalicum [208] and Gliocladium sp. T31 [209], which was investigated for antitumor
properties as a DNA topoisomerase I inhibitor [210]. This compound showed a potent cytotoxicity on
MDR cells (P-gp, MRP1, and BCRP-overexpressing cells) and on their parental cells by down-regulating
the expression of BCRP protein [211]. It also decreased the percentage of side population cell in lung
cancer cells. These results highlight 105 as an interesting molecule that has a potent cytotoxic activity
by enduring BCRP degradation, and was considered as a lead compound for the development of new
BCRP inhibitors [212].
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Scheme 21. Total synthesis of secalonic acid D (105). Reagents and conditions: (1) 2,6-lutidine, iPrSi(OTf)2,
CH2Cl2, then Et3N¨ 3HF; (2) Rh/Al2O3, H2, MeOH; (3) NaH, THF; (4) CH2Cl2, then NaH, THF.
Chemicall , secal nic acid D (105) is the chiral dimeric natural pro uct of ergochrome
xanthone [213]. The synthesis of secalonic acid D (105) started from the intermediate compound
(˘)-blennolide B, which was synthesized from 5-hydroxychromone, with a construction of a
hemisecalonic derivative, followed by the conversion with iodide and stannane. This reaction is
a copper-catalyzed C–C bond-forming between the two molecules under oxidative conditions as the
key dimerization step. This reaction is the first challenge to oxidize the xanthone framework which
was previously shown as unsuitable for a direct oxidation. The iodide compound can be preactivated
at an o-position to make the dimerization regioselective. The total synthesis of secalonic acid D (105) is
illustrated in Scheme 21 [213–216].
2.7.3. Terrein
Terrein (106, Scheme 22) is a fungal metabolite isolated from the marine-derived thermophilic
fungus Aspergillus terreus. This metabolite has been already reported to inhibit cell proliferation, to
induce cell cycle arrest in human ovarian tumor cells (SKOV3,) and to inhibit the proliferation of
ovarian cancer stem-like cells [217], to inhibit the epidermal proliferation of skin [218], as well as to
inhibit melanogenesis [219]. It also displayed a strong cytotoxicity against breast cancer (MCF-7) cell
and suppressed the growth of MCF-7 expressing BCRP cells by inducing apoptosis caspase-7 pathway,
and inhibiting the Akt signaling pathway [220].
A simple synthesis of (+)-terrein (106) was reported by using L-tartrate or dimethyl L-tartrate
as starting materials. The whole process included cyclization, Horner-Wadsworth-Emmons, and
deprotection of bis-t-butyldimethylsilyl (bis-TBS) group as shown in Scheme 22 [221].
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2.7.4. Shornephine A
Shornephine A (107, Figure 22) is a diketomorpholine isolated from the marine fungus
Aspergillus sp. (CMC-M081F) which was collected from marine sediment. This compound was
described as non-cytotoxic against bacteria, fungus, and tumor cell lines and an inhibitor of P-gp in
MDR human colon tumor cells (SW60 Ad300) at the concentration of 20 µM [222].
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3. Future Perspectives
We are now witnessing a renaissance of the interest in efflux transporters, not only due to
regulatory requirements but also to the significant role of these carriers in the adsorption, distribution,
metabolism, excretion, and toxicity (ADMET) process of drug discovery. Therefore, P-gp and other
ABC transporters that mediate drug efflux are recognized as a “team to beat”. Marine organisms have
proven to be an important source in the discovery and development of interesting compounds, and,
in particular, of anticancer agents. These marine-derived compounds, which can be grouped mainly
as alkaloids, polyoxygenated sterols, terpenoids, and peptides, have demonstrated a reversal effect
of MDR by themselves. Some compounds were shown to increase rather than decrease cytotoxicity
towards MDR cell lines and can be defined as collateral sensitizing agents or this effect was shown in
co bination with anticancer drugs, being non-cytotoxic MDR reversal agents. The major sources of
marine MDR reversal agents and mechanisms have been scarcely studied, and very little is known
about their mechanism of action. Several marine compounds which have shown potent and selective
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MDR activity against cancer cell lines belong to the alkaloids; however, they present some toxicity.
Among marine natural products, trabectedin has proved to be the most promising against MDR with
in vitro and in vivo efficacy. Chemically, synthetic analogs of marine compounds acting as inhibitors
have been investigated to achieve higher activity, less toxicity and less pharmacokinetic interaction
properties, and to establish SAR. With this diversity of scaffolds it is not possible to extract common
features essential for MDR reversal activity; however, most of the derivatives are highly lipophilic
and contain fused rings and multiple chiral centers, which in turn reflect their complex total synthesis
procedures. Among the synthetic analogs, eriburin has been shown to be the most promising P-gp
modulator, active against MDR in vitro and with proved safety in clinical patients. These features also
open new challenges for medicinal chemists to accomplish viable synthetic routes and new avenues in
the design of analogs with suitable drug-like properties that could render potential drug candidates.
Joining together all the pieces of the chemical-biological-pharmaceutical puzzle, we can anticipate
more effective chemotherapies based on molecules from the sea.
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